Shots:

• The conditional approval is based on P-Ib/II GO29365 study assessing Polivy + bendamustine and MabThera (rituximab) (BR) or Gazyvaro (obinutuzumab) vs BR in R/R FL or DLBCL patients who are not the candidates for a hematopoietic stem cell transplant
• The P-Ib/II GO29365 study results: CR (40% vs 17.5%); improvement in OS (12.4 vs 4.7); the longer time between first response to treatment and disease worsening (10.3 vs 4.1 mos.)
• Polivy is an ADC targeting CD79b- developed by utilizing Seattle Genetics’ ADC technology and has received FDA’s BT and EMA’s PRIME designation to treat people with r/r DLBCL in 2017. The conditional approval follows the US FDA’s accelerated approval granted in Jun’2019

Click here ­to­ read full press release/ article 

 Ref: Roche | Image: Roche